淋巴管浸润(LVSI)定义为肿瘤细胞存在于浸润癌周围器官的确定的内皮衬里空间(淋巴管或血管)内。LVI的存在与淋巴结和远处转移的风险增加有关。淋巴管浸润被描述为血管或淋巴管内的癌症,是转移的独立危险因素。复发,和死亡率。这项研究旨在提出子宫内膜高级别腺癌中LVSI周围细胞的基于标记的免疫组织学表征,以建立LVSI细胞的细胞图谱。介绍了一名67岁的女性患者侵袭性高级别浆液性子宫内膜腺癌的淋巴血管间隙侵袭周围细胞的细胞特征。手术后一小时内从同意的浸润性高级别浆液性子宫内膜腺癌患者中获得切除的肿瘤组织。上皮标志物(CK8、18和EpCAM)的表达,LCA(白细胞共同抗原)标记(CD45),增殖标记(Ki67),凋亡标志物(裂解的PARP和裂解的caspase3),免疫细胞标志物(CD3,CD4,CD8,CD56,CD68,CD163,FoxP3,PD-1,PD-L1),促炎标志物(IL-12-RB2),和成纤维细胞/间质标记(S100A7,SMA,和TE-7)切除的组织在IHC染色上进行评估,并由病理学家进行评分。承认LVSI在子宫内膜高级别腺癌中的决定性作用,我们的研究提出了第一个基于标志物的肿瘤和TME区室在上皮细胞标志物的背景下的免疫组织学图谱,增殖标记,凋亡标志物,巨噬细胞标记物,和成纤维细胞标记。我们的研究表明,子宫内膜高级别腺癌等侵袭性疾病通过涉及肿瘤和TME的免疫景观而引起LVSI的前转移事件。这项研究表明,第一次,LVSI内的肿瘤细胞对IL-12R-B2和S100A4呈阳性。
Lymphovascular invasion (LVSI) is defined as the presence of tumor cells within a definite endothelial-lined space (lymphatics or blood vessels) in the organ surrounding invasive carcinoma. The presence of LVI is associated with an increased risk of lymph nodes and distant metastases. Lymphovascular invasion is described as cancer within blood or lymph vessels and is an independent risk factor for metastasis, recurrence, and mortality. This study aims to present the marker-based immunohistological characterization of cells around LVSI in a high-grade adenocarcinoma of the endometrium to build a cellular atlas of cells of LVSI. A cellular characterization of the cells around lymphovascular space invasion in a 67-year-old female patient with invasive high-grade serous endometrial adenocarcinomas is presented. Resected tumor tissue from a consented patient with invasive high-grade serous endometrial adenocarcinoma was obtained within an hour of surgery. The expressions of the epithelial markers (CK8, 18, and EpCAM), LCA (leukocyte common antigen) marker (CD45), proliferation marker (Ki67), apoptosis markers (cleaved PARP and cleaved caspase3), immune cell markers (CD3, CD4, CD8, CD56, CD68, CD163, FoxP3, PD-1, PD-L1), pro-inflammatory marker (IL-12-RB2), and fibroblast/mesenchyme markers (S100A7, SMA, and TE-7) of the resected tissue on the IHC stains were evaluated and scored by a pathologist. Acknowledging the deterministic role of LVSI in a high-grade adenocarcinoma of the endometrium, our study presents the first marker-based immunohistological atlas of the tumor and TME compartments in the context of epithelial cell markers, proliferation markers, apoptosis markers, macrophage markers, and fibroblast markers. Our study demonstrates that an aggressive disease like a high-grade adenocarcinoma of the endometrium inflicts the pro-metastatic event of LVSI by involving the immune landscape of both tumor and TME. This study demonstrates, for the first time, that the tumor cells within LVSI are positive for IL-12R-B2 and S100A4.